Tharimmune makes a pivot into digital assets, raises approximately $540 million via a private placement

Tharimmune, Inc., a clinical-stage biotechnology company traditionally focused on developing therapies for rare immune, inflammatory, and oncologic diseases, has just announced its pivot into digital assets, raising approximately $540 million via a private placement led by proprietary trading firm DRW and crypto-focused venture capital firm Liberty City Ventures. According to Tharimmune, Inc.’s announcement today, it has entered into subscription agreements with certain institutional and accredited investors in a private placement offering for the purchase and sale of shares of common stock at a price of $3.075 per share. The arrangement is expected to aggregate gross proceeds of approximately $540 million,...